Anichini A, Maccalli C, Mortarini R, Salvi S, Mazzocchi A, Squarcina P, Herlyn M, Parmiani G
Division of Experimental Oncology D, Istituto Nazionale Tumori, Milan, Italy.
J Exp Med. 1993 Apr 1;177(4):989-98. doi: 10.1084/jem.177.4.989.
HLA-A2-restricted, CD3+, CD8+, alpha/beta+ cytotoxic T cell (CTL) clones were isolated from peripheral blood (PBL) or tumor infiltrating lymphocytes (TIL) of two HLA-A2+ melanoma patients (9742 and 5810), to evaluate the possible recognition of autologous melanoma and of allogeneic HLA-A2-matched normal melanocytes. These CTL clones lysed not only fresh and cultured autologous melanoma cells, but also allogeneic HLA-A2+, but not HLA-A2-, normal melanocytes. The lysis of autologous neoplastic cells and of melanocytes could be inhibited by an anti-HLA-A2 monoclonal antibody (mAb). Lysis of the normal melanocytes was not dependent on the presence of human or fetal calf serum in the culture medium. HLA-A2-restricted CTL clones recognized not only proliferating melanocytes cultured in complete melanocyte medium, but also melanocytes made quiescent by culture for up to 6 d in a basal medium devoid of exogenous factors such as phorbol ester (O-tetradecanoyl phorbol 13-acetate [TPA]), epidermal growth factor, insulin, and pituitary extracts. Analysis of specificity of four CTL clones (A75, A83, A94, and 119) from patient 9742, performed on a panel of 39 targets, indicated that the three HLA-A2-restricted CTL (A75, A83, and A94) lysed all but one of nine allogeneic melanomas expressing the HLA-A2 molecule with no reactivity on nine HLA-A2- allogeneic melanomas. Only a few instances of borderline reactivity were seen by the same effectors on 21 targets of nonmelanocyte lineage, including 12 carcinomas of different histology, four Epstein-Barr virus-transformed B cells (lymphoblastoid cell lines [LCL]), including the autologous LCL, four lines of normal fibroblasts, and normal kidney cells. Lack of reactivity on allogeneic targets of nonmelanocyte lineage occurred in spite of expression of HLA-A2 on 14 of these targets as determined by conventional tissue typing and cytofluorimetric analysis with four different anti-HLA-A2 mAb. These data indicate that tissue-related antigens can be expressed on normal and neoplastic cells of the melanocyte lineage and can be recognized in association with HLA-A2 by CTL clones from melanoma patients.
从两名HLA - A2阳性黑色素瘤患者(9742和5810)的外周血(PBL)或肿瘤浸润淋巴细胞(TIL)中分离出HLA - A2限制性、CD3 +、CD8 +、α/β +细胞毒性T细胞(CTL)克隆,以评估其对自体黑色素瘤和同种异体HLA - A2匹配的正常黑素细胞的可能识别情况。这些CTL克隆不仅能裂解新鲜的和培养的自体黑色素瘤细胞,还能裂解同种异体HLA - A2 +但不能裂解HLA - A2 -的正常黑素细胞。自体肿瘤细胞和黑素细胞的裂解可被抗HLA - A2单克隆抗体(mAb)抑制。正常黑素细胞的裂解不依赖于培养基中是否存在人或胎牛血清。HLA - A2限制性CTL克隆不仅能识别在完全黑素细胞培养基中培养的增殖性黑素细胞,还能识别在不含佛波酯(十四酰佛波醇13 -乙酸酯[TPA])、表皮生长因子、胰岛素和垂体提取物等外源性因子的基础培养基中培养长达6天而静止的黑素细胞。对来自患者9742的四个CTL克隆(A75、A83、A94和119)进行的特异性分析,在一组39个靶标上进行,结果表明,三个HLA - A2限制性CTL(A75、A83和A94)能裂解九个表达HLA - A2分子的同种异体黑色素瘤中的除一个之外的所有肿瘤,而对九个HLA - A2 -的同种异体黑色素瘤无反应性。相同的效应细胞对21个非黑素细胞系靶标仅有少数临界反应情况,包括12种不同组织学类型的癌、4种爱泼斯坦 - 巴尔病毒转化的B细胞(淋巴母细胞系[LCL]),包括自体LCL、4种正常成纤维细胞系和正常肾细胞。尽管通过传统组织分型和用四种不同抗HLA - A2 mAb进行细胞荧光分析确定其中14个靶标表达HLA - A2,但对非黑素细胞系同种异体靶标仍无反应性。这些数据表明,组织相关抗原可在黑素细胞系的正常细胞和肿瘤细胞上表达,并可被黑色素瘤患者的CTL克隆与HLA - A2结合识别。